OncoMyx Therapeutics utilizes a patented systemic delivery method for the myxoma virus, an oncolytic agent that selectively infects and destroys hematologic and solid tumor cells while stimulating the immune response. The company addresses the challenge of effective cancer treatment by leveraging the virus's unique ability to be transported by human leukocytes to target tumors directly.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments lack the specificity to target tumor cells effectively, leading to systemic toxicity and limited efficacy, especially in hard-to-reach or drug-resistant tumors. Traditional oncolytic virus therapies often struggle with effective delivery and immune evasion, hindering their ability to reach and destroy cancer cells throughout the body.
Solution
OncoMyx Therapeutics is developing a targeted cancer therapy using the myxoma virus, an oncolytic virus with a natural tropism for cancer cells. The company's approach leverages the virus's ability to selectively infect and lyse tumor cells while simultaneously stimulating an anti-tumor immune response. By utilizing a patented systemic delivery method, OncoMyx aims to overcome the limitations of traditional oncolytic virus therapies, enabling the virus to be transported by human leukocytes directly to tumor sites, including hematologic and solid tumors. This targeted delivery enhances the virus's efficacy while minimizing off-target effects, potentially improving patient outcomes.
Target Audience
The primary target audience includes cancer patients with advanced or drug-resistant tumors, as well as oncologists and researchers seeking novel and targeted therapeutic options.
Features
- Patented systemic delivery method for enhanced tumor targeting
- Myxoma virus selectively infects and destroys cancer cells
- Stimulation of anti-tumor immune response
- Potential for treating both hematologic and solid tumors